首页> 美国卫生研究院文献>Experimental and Therapeutic Medicine >Down-regulation of CXCR7 inhibits the growth and lung metastasis of human hepatocellular carcinoma cells with highly metastatic potential
【2h】

Down-regulation of CXCR7 inhibits the growth and lung metastasis of human hepatocellular carcinoma cells with highly metastatic potential

机译:CXCR7的下调抑制具有高转移潜力的人肝癌细胞的生长和肺转移

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

CXCR7, a recently identified chemokine receptor, has been implicated in directing cancer metastasis. In the present study, the potential roles of CXCR7 in the growth and metastasis of hepatocellular carcinoma (HCC) were evaluated. A chemokine receptor gene chip was used to compare the expression of CXCR7 in HCC cell lines with different metastatic potential. Effects of targeting CXCR7 by RNA interference (RNAi) on the proliferation and metastasis of HCCLM3 cells were observed in vitro and in vivo. CXCR7 expression in 116 specimens from patients with or without metastatic HCC was assessed by tissue microarray. As a result, the gene chip showed that expression of CXCR7 was significantly higher in the highly metastatic HCCLM3 cells, which was confirmed by real-time RT-PCR and Western blotting. Chemotaxis assays showed that HCCLM3 cells responded to SDF-1α from 1 to 100 μg/l and lung extractions (1 g/l). Furthermore, down-regulation of CXCR7 in HCCLM3 cells by RNAi inhibited the proliferation and invasion of tumor cells in vitro. Moreover, CXCR7 knockdown significantly reduced the activity of matrix metalloproteinase-2 and matrix metalloproteinase-9. RNAi of CXCR7 in the HCCLM3 cells also decreased the growth of tumors and the number of lung metastases in nude mice. The tissue microarray showed that HCCs with high expression of CXCR7 were prone to metastasize to the lung. These findings suggest that CXCR7 plays critical roles in the growth and metastasis of HCC. RNAi of CXCR7 inhibits the growth and invasion of tumor cells, which indicates that CXCR7 may be a potential molecular target for use in HCC therapy.
机译:最近鉴定出的趋化因子受体CXCR7与癌症转移有关。在本研究中,评估了CXCR7在肝细胞癌(HCC)生长和转移中的潜在作用。使用趋化因子受体基因芯片比较了具有不同转移潜能的HCC细胞中CXCR7的表达。在体外和体内观察到通过RNA干扰(RNAi)靶向CXCR7对HCCLM3细胞增殖和转移的影响。通过组织微阵列评估了116例有或没有转移性肝癌患者的CXCR7表达。结果,该基因芯片显示在高度转移的HCCLM3细胞中CXCR7的表达明显更高,这已通过实时RT-PCR和Western印迹证实。趋化分析显示,HCCLM3细胞对SDF-1α的响应为1至100μg/ l,而肺提取物的响应为(1 g / l)。此外,RNAi对HCCLM3细胞中CXCR7的下调在体外抑制了肿瘤细胞的增殖和侵袭。此外,CXCR7组合式大大降低了基质金属蛋白酶2和基质金属蛋白酶9的活性。 HCCLM3细胞中CXCR7的RNAi也降低了裸鼠体内肿瘤的生长和肺转移的数量。组织芯片显示,高表达CXCR7的HCC易于转移到肺部。这些发现表明,CXCR7在肝癌的生长和转移中起关键作用。 CXCR7的RNAi抑制肿瘤细胞的生长和侵袭,这表明CXCR7可能是用于HCC治疗的潜在分子靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号